The Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies

Objective A total of 48% of patients with Parkinson's disease (PD) present symptoms of gastrointestinal dysfunction, particularly constipation. Furthermore, gastrointestinal tract (GIT)-related non-motor symptoms (NMSs) appear at all stages of PD, can be prodromal by many years and have a relevant impact on the quality of life. There is a lack of GIT-focused validated tools specific to PD to assess their occurrence, progress, and response to treatment. The aim of this study was to develop and evaluate a novel, disease- and symptom-specific, self-completed questionnaire, titled Gut Dysmotility Questionnaire (GDQ), for screening and monitoring gastrointestinal dysmotility of the lower GIT in patients with PD. Methods In phase 1, a systematic literature review and multidisciplinary expert discussions were conducted. In phase 2, cognitive pretest studies comprising standard pretests, interviews, and evaluation questionnaires were performed in patients with PD (n = 21), age- and sex-matched healthy controls (HC) (n = 30), and neurologists (n = 11). Incorporating these results, a second round of cognitive pretests was performed investigating further patients with PD (n = 10), age- and sex-matched HC (n = 10), and neurologists (n = 5). The questionnaire was adapted resulting in the final GDQ, which underwent cross-cultural adaptation to the English language. Results We report significantly higher GDQ total scores and higher scores in five out of eight domains indicating a higher prevalence of gastrointestinal dysmotility in patients with PD than in HC (p < 0.05). Cognitive pretesting improved the preliminary GDQ so that the final GDQ was rated as relevant (100/100%), comprehensive (100/90%), easy to understand concerning questions and answer options (100/90%), and of appropriate length (80/100%) by neurologists and patients with PD, respectively. The GDQ demonstrated excellent internal consistency (Cronbach‘s alpha value of 0.94). Evidence for good construct validity is given by moderate to high correlations of the GDQ total score and its domains by intercorrelations (rs = 0.67–0.91; p < 0.001) and with validated general NMS measures as well as with specific items that assess gastrointestinal symptoms. Interpretation The GDQ is a novel, easy, and quick 18-item self-assessment questionnaire to screen for and monitor gastrointestinal dysmotility with a focus on constipation in patients with PD. It has shown high acceptance and efficacy as well as good construct validity in cognitive pretests.

[1]  C. Williams-Gray,et al.  The Gastrointestinal Dysfunction Scale for Parkinson's Disease , 2021, Movement disorders : official journal of the Movement Disorder Society.

[2]  D. Aarsland,et al.  Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts. , 2021, Journal of Parkinson's disease.

[3]  K. Chaudhuri,et al.  Prevalence of Non‐Motor Symptoms and Non‐Motor Fluctuations in Parkinson's Disease Using the MDS‐NMS , 2020, Movement disorders clinical practice.

[4]  Ming-Hong Chang,et al.  Is there a close association of depression with either constipation or dysosmia in Parkinson’s disease? , 2020, Scientific Reports.

[5]  D. Brooks,et al.  Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. , 2020, Brain : a journal of neurology.

[6]  K. Chaudhuri,et al.  Pilot Study of the International Parkinson and Movement Disorder Society‐sponsored Non‐motor Rating Scale (MDS‐NMS) , 2019, Movement disorders clinical practice.

[7]  R. Pfeiffer Gastrointestinal Dysfunction in Parkinson’s Disease , 2018, Current Treatment Options in Neurology.

[8]  K. Chaudhuri,et al.  Non-motor features of Parkinson disease , 2017, Nature Reviews Neuroscience.

[9]  K. Krogh,et al.  Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives , 2017, Movement disorders : official journal of the Movement Disorder Society.

[10]  S. Hamilton-Dutoit,et al.  Pathological α‐synuclein in gastrointestinal tissues from prodromal Parkinson disease patients , 2016, Annals of neurology.

[11]  D. Drossman,et al.  Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. , 2016, Gastroenterology.

[12]  H. Reichmann,et al.  Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors , 2015, Nature Reviews Neurology.

[13]  Günther Deuschl,et al.  MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[14]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[15]  L. Timmermann,et al.  Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial. , 2015, Parkinsonism & related disorders.

[16]  E. Tolosa,et al.  Multiple organ involvement by alpha‐synuclein pathology in Lewy body disorders , 2014, Movement disorders : official journal of the Movement Disorder Society.

[17]  H. Reichmann,et al.  Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice , 2012, Scientific Reports.

[18]  E. Quigley,et al.  Gastroparesis and Parkinson's disease: a systematic review. , 2012, Parkinsonism & related disorders.

[19]  K. Chaudhuri,et al.  The impact of non‐motor symptoms on health‐related quality of life of patients with Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[20]  Angelo Antonini,et al.  Levodopa in the treatment of Parkinson’s disease: an old drug still going strong , 2010, Clinical interventions in aging.

[21]  Marios Politis,et al.  Parkinson's disease symptoms: The patient's perspective , 2010, Movement disorders : official journal of the Movement Disorder Society.

[22]  H. Shill,et al.  Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders , 2010, Acta Neuropathologica.

[23]  Angelo Antonini,et al.  The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[24]  W. Poewe,et al.  Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation—Critique and recommendations by movement disorders task force on rating scales for Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[25]  Paolo Barone,et al.  The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[26]  C. Tanner,et al.  Bowel movement frequency in late‐life and incidental Lewy bodies , 2007, Movement disorders : official journal of the Movement Disorder Society.

[27]  Paolo Barone,et al.  International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[28]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[29]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.

[30]  J. Fisk,et al.  A comparison of health utility measures for the evaluation of multiple sclerosis treatments , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[31]  Johan Marinus,et al.  Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUT , 2004, Movement disorders : official journal of the Movement Disorder Society.

[32]  H. Braak,et al.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.

[33]  C Trenkwalder,et al.  The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[34]  C. Tanner,et al.  Frequency of bowel movements and the future risk of Parkinson’s disease , 2001, Neurology.

[35]  C. Bombardier,et al.  Guidelines for the process of cross-cultural adaptation of self-report measures. , 2000, Spine.

[36]  K. Chaudhuri,et al.  General approach to patients with autonomic dysfunction in Parkinson's disease , 2021, Autonomic Dysfunction in Parkinson's Disease.

[37]  K. Walters,et al.  Prediagnostic presentations of Parkinson's disease in primary care: a case-control study , 2015, The Lancet Neurology.

[38]  E. Katunina,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[39]  I. Bernstein,et al.  Psychometric theory : Nunnally and Bernstein, 3rd edition , 2007 .

[40]  J. Conley Asking questions: A practical guide to questionnaire design , 1983 .